VistaGen Therapeutics
VTGN
28 hedge funds and large institutions have $2.39M invested in VistaGen Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
80% more capital invested
Capital invested by funds: $1.33M → $2.39M (+$1.06M)
12% more funds holding
Funds holding: 25 → 28 (+3)
0.02% less ownership
Funds ownership: 0.16% → 0.15% (-0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$538K |
| 2 |
Goldman Sachs
New York
|
+$97.5K |
| 3 |
Renaissance Technologies
New York
|
+$77.3K |
| 4 |
Two Sigma Advisers
New York
|
+$19.9K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$39.5K |
| 2 |
Jane Street
New York
|
-$38K |
| 3 |
SCM
Sitrin Capital Management
Century City,
California
|
-$23K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$18.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Koshinski Asset Management
Decatur,
Illinois
| $15 | – | – | – |
|
|
27
Jane Street
New York
| – | -$38K | -2,432 | Closed |
|
|
SCM
28
Sitrin Capital Management
Century City,
California
| – | -$23K | -1,478 | Closed |
|
29
Wells Fargo
San Francisco,
California
| – | +$83 | +4 | +40% |
|
VTGN Hedge Fund Activity: Q3 2020 in Review
28 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2020, worth a combined $2.39M — up 80% from $1.33M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VTGN positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $538K. The largest seller was UBS Group, cutting an estimated $39.5K.
- 28 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2020, up from 25 in Q2 2020.
- Funds reported $2.39M of VistaGen Therapeutics stock for Q3 2020, up 80% quarter-over-quarter.
- 5 funds opened new VistaGen Therapeutics positions in Q3 2020 and 2 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $538K added.
- The largest VistaGen Therapeutics seller in Q3 2020 was UBS Group, an estimated $39.5K sold.
Based on aggregated 13F filings for Q3 2020.